Evidence map›Paper›PMID 18832723›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2008

Sumoylation of peroxisome proliferator-activated receptor gamma by apoptotic cells prevents lipopolysaccharide-induced NCoR removal from kappaB binding sites mediating transrepression of proinflammatory cytokines.

Carla Jennewein, Anne-Marie Kuhn, Martina Victoria Schmidt, Virginie Meilladec-Jullig, Andreas von Knethen, Frank J Gonzalez, Bernhard Brüne

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 113 citations in OpenAlex.

  1. Article
  2. Immune regulation by the SUMO family.Nature reviews. Immunology · 2025
    Review
  3. Review
  4. iScience · 2022
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Role of Epigenetics in the Regulation of Immune Functions of the Skin.The Journal of investigative dermatology · 2021
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Efferocytosis in health and disease.Nature reviews. Immunology · 2020
    Review
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Carla JenneweinInstitute of Biochemistry I/Zentrum für Arzneimittelforschung, -Entwicklung und -Sicherheit, Faculty of Medicine, Goethe-University Frankfurt am Main, Frankfurt, Germany.
Anne-Marie Kuhn
Martina Victoria Schmidt
Virginie Meilladec-Jullig
Andreas von Knethen
Frank J Gonzalez
Bernhard Brüne
Goethe University Frankfurt · DENational Cancer Institute · US

Funding

Xenobiotic ReceptorsZIABC005708 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GONZALEZ, FRANK J · 2009 to 2025
$16.4M
Xenobiotic ReceptorsZ01BC005708 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GONZALEZ, FRANK J · 1996 to 2008
$1.7M
Intramural NIH HHS Z01 BC005708
6 · The paper itself

Abstract

Efficient clearance of apoptotic cells (AC) by professional phagocytes is crucial for tissue homeostasis and resolution of inflammation. Macrophages respond to AC with an increase in antiinflammatory cytokine production but a diminished release of proinflammatory mediators. Mechanisms to explain attenuated proinflammatory cytokine formation remain elusive. We provide evidence that peroxisome proliferator-activated receptor gamma (PPARgamma) coordinates antiinflammatory responses following its activation by AC. Exposing murine RAW264.7 macrophages to AC before LPS stimulation reduced NF-kappaB transactivation and lowered target gene expression of, that is, TNF-alpha and IL-6 compared with controls. In macrophages overexpressing a dominant negative mutant of PPARgamma, NF-kappaB transactivation in response to LPS was restored, while macrophages from myeloid lineage-specific conditional PPARgamma knockout mice proved that PPARgamma transmitted an antiinflammatory response, which was delivered by AC. Expressing a PPARgamma-Delta aa32-250 deletion mutant, we observed no inhibition of NF-kappaB. Analyzing the PPARgamma domain structures within aa 32-250, we anticipated PPARgamma sumoylation in mediating the antiinflammatory effect in response to AC. Interfering with sumoylation of PPARgamma by mutating the predicted sumoylation site (K77R), or knockdown of the small ubiquitin-like modifier (SUMO) E3 ligase PIAS1 (protein inhibitor of activated STAT1), eliminated the ability of AC to suppress NF-kappaB. Chromatin immunoprecipitation analysis demonstrated that AC prevented the LPS-induced removal of nuclear receptor corepressor (NCoR) from the kappaB site within the TNF-alpha promoter. We conclude that AC induce PPARgamma sumoylation to attenuate the removal of NCoR, thereby blocking transactivation of NF-kappaB. This contributes to an antiinflammatory phenotype shift in macrophages responding to AC by lowering proinflammatory cytokine production.

Indexed as

Amino Acid SequenceAnimalsApoptosisHumansInflammation MediatorsInterleukin-6Jurkat CellsLipopolysaccharidesMacrophagesMiceMice, KnockoutNF-kappa BNuclear ProteinsNuclear Receptor Co-Repressor 1PPAR gammaProtein Inhibitors of Activated STATIL6 protein, humanInflammation MediatorsInterleukin-6LipopolysaccharidesNCOR1 protein, humanNcor1 protein, mouseNF-kappa BNuclear ProteinsNuclear Receptor Co-Repressor 1PIAS1 protein, humanPias1 protein, mousePPAR gammaProtein Inhibitors of Activated STATRepressor ProteinsSmall Ubiquitin-Related Modifier ProteinsSUMO-1 ProteinTumor Necrosis Factor-alpha

Identifiers

PMID18832723
PMCPMC2679654
OpenAlexW1913383562

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.